Efficacy and safety of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Using chemotherapy or chemoradiotherapy (CRT) as the main treatment strategy for unresectable locally advanced pancreatic ductal adenocarcinoma (UR-LA PDAC) remains controversial. This study aimed to evaluate the efficacy and safety of CRT combined with gemcitabine plus nab-paclitaxel in patients with UR-LA PDAC. Eight patients with UR-LA PDAC were eligible for inclusion. Nab-paclitaxel (100 mg/m 2 ) and gemcitabine (800 mg/m 2 or 1000 mg/m 2 ) were administered on days 1 and 8 per 3-week cycle repeated for two cycles with concurrent radiation therapy (50.4 Gy/28 fractions/6 weeks). After this regimen was administered, conversion surgery was considered if the tumor was reduced in size, and we judged the tumor to be resectable. No CRT-related mortality was observed during CRT. Three patients failed to complete this regimen because of neutropenia and hepatic impairment. The treatment completion and resection rates were 62.5% (5/8) and 25.0% (2/8), respectively. Curative resection (R0) was performed in two patients (100%). The 1-and 3-year overall survival rates were 37.5% and 25.0%, respectively, with a median follow-up period of 355 (range, 226 − 1450) days. CRT with 100 mg/m 2 nab-paclitaxel and 800 mg/m 2 gemcitabine with 50.4 Gy radiation was well tolerated and safe,but most UR-LA PDAC patients require additional treatment, suggesting CRT limitations.